[1]
|
International Agency for Research on Cancer (2014) Cancer Incidence in Five Continents Volume X (IARC, 2014).
|
[2]
|
Shi, Y., Xing, P., Fan, Y., et al. (2015) Current Small Cell Lung Cancer Treatment in China. Thoracic Can-cer, 6, 233-238. https://doi.org/10.1111/1759-7714.12218
|
[3]
|
赫捷, 魏文强. 2019中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2021: 145.
|
[4]
|
Sardarabadi, P., Kojabad, A.A., Jafari, D. and Liu, C.H. (2021) Liquid Biop-sy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC). Biosen-sors (Basel), 11, Article No. 394.
https://doi.org/10.3390/bios11100394
|
[5]
|
Sun, Q., Li, W., Liu, T. and Guo, H. (2022) Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. Frontiers in Oncology, 12, Article ID: 916681.
https://doi.org/10.3389/fonc.2022.916681
|
[6]
|
Ryan, J. and Malinga, T. (2021) Interventions for Vaccine Hesitan-cy. Current Opinion in Immunology, 71, 89-91.
https://doi.org/10.1016/j.coi.2021.05.003
|
[7]
|
Wang, Y., Shi, T., Song, X., Liu, B. and Wei, J. (2021) Gene Fusion Neoantigens: Emerging Targets for Cancer Immunotherapy. Cancer Letters, 506, 45-54. https://doi.org/10.1016/j.canlet.2021.02.023
|
[8]
|
Evans, R., Reid, M., Segal, B., Abrams, S.I. and Lee, K. (2018) Case Study in International Cooperation: Cuba’s Molecular Immunology Center and Roswell Park Cancer Institute. MEDICC Review, 20, 35-39.
https://doi.org/10.37757/MR2018.V20.N2.8
|
[9]
|
Rodríguez, P.C., Rodríguez, G., González, G. and Lage, A. (2010) Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-Small-Cell Lung Cancer Therapy. MEDICC Review, 12, 17-23.
https://doi.org/10.37757/MR2010.V12.N1.4
|
[10]
|
Cheng, J.Y. and Kananathan, R. (2012) CIMAvax EGF Vaccine for Stage IIIb/IV Non-Small Cell Lung Carcinoma. Human Vaccines & Immunotherapeutics, 8, 1799-1801. https://doi.org/10.4161/hv.21744
|
[11]
|
Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J.R., Bha-rat, A., et al. (2021) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19, 254-266. https://doi.org/10.6004/jnccn.2021.0013
|
[12]
|
张佳颖, 朱磊, 杨宏宽, 等. CIMAvax-EGF在非小细胞肺癌中的治疗进展[J]. 中国医学科学院学报, 2018, 40(3): 411-414.
|
[13]
|
Sellars, M.C., Wu, C.J. and Fritsch, E.F. (2022) Cancer Vaccines: Building a Bridge over Troubled Wa-ters. Cell, 185, 2770-2788. https://doi.org/10.1016/j.cell.2022.06.035
|
[14]
|
Saavedra, D., Neninger, E., Rodriguez, C., Viada, C., Mazorra, Z., Lage, A. and Crombet, T. (2018) CIMAvax-EGF: Toward Long-Term Survival of Advanced NSCLC. Seminars in Oncology, 45, 34-40.
https://doi.org/10.1053/j.seminoncol.2018.04.009
|
[15]
|
Castells Martínez, E.M., Del Valle, R., González, E.C., Melchor, A., Pérez, P.L., González, I., Carr, A. and León, K. (2017) An Enzyme Immunoassay for Determining Epider-mal Growth Factor (EGF) in Human Serum Samples Using an Ultramicroanalytical System. Journal of Immunoassay and Immunochemistry, 38, 190-201.
https://doi.org/10.1080/15321819.2016.1236729
|
[16]
|
Crombet Ramos, T., Rodríguez, P.C., NeningerVinageras, E., Garcia Verdecia, B. and Lage Davila, A. (2015) CIMAvax EGF (EGF-P64K) Vaccine for the Treatment of Non-Small-Cell Lung Cancer. Expert Review of Vaccines, 14, 1303-1311. https://doi.org/10.1586/14760584.2015.1079488
|
[17]
|
Popa, X., García, B., Fuentes, K.P., Huerta, V., Alvarez, K., Viada, C.E., et al. (2020) Anti-EGF Antibodies as Surrogate Biomarkers of Clinical Efficacy in Stage IIIB/IV Non-Small-Cell Lung Cancer Patients Treated with an Optimized CIMAvax-EGF Vaccination Schedule. Oncoimmunol-ogy, 9, Article ID: 1762465.
https://doi.org/10.1080/2162402X.2020.1762465
|
[18]
|
Rodriguez, P.C., Popa, X., Martínez, O., Mendoza, S., San-tiesteban, E., Crespo, T., et al. (2016) A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non- Small Cell Lung Cancer Patients. Clinical Cancer Research, 22, 3782-3790.
https://doi.org/10.1158/1078-0432.CCR-15-0855
|
[19]
|
Saavedra, D. and Crombet, T. (2017) CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Frontiers in Immunology, 8, Article No. 269. https://doi.org/10.3389/fimmu.2017.00269
|
[20]
|
Lorenzo-Luaces, P., Sanchez, L., Saavedra, D., Crombet, T., Van der Elst, W., Alonso, A., Molenberghs, G. and Lage, A. (2020) Identifying Predictive Biomarkers of CIMAvaxEGF Success in Non-Small Cell Lung Cancer Patients. BMC Cancer, 20, Article No. 772. https://doi.org/10.1186/s12885-020-07284-4
|
[21]
|
Tagliamento, M., Rijavec, E., Barletta, G., Biello, F., Rossi, G., Grossi, F. and Genova, C. (2018) CIMAvax-EGF, a Therapeutic Non-Small Cell Lung Cancer Vaccine. Expert Opinion on Biological Therapy, 18, 829-835.
https://doi.org/10.1080/14712598.2018.1492539
|
[22]
|
Crombet Ramos, T., Santos Morales, O., Dy, G.K., León Monzón, K. and Lage Dávila, A. (2021) The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 11, Article ID: 639745. https://doi.org/10.3389/fonc.2021.639745
|
[23]
|
Evans, R., Lee, K., Wallace, P.K., Reid, M., Muhitch, J., Dozier, A., et al. (2022) Augmenting Antibody Response to EGF-Depleting Immunotherapy: Findings from a Phase I Trial of CI-MAvax-EGF in Combination with Nivolumab in Advanced Stage NSCLC. Frontiers in Oncology, 12, Article ID: 958043. https://doi.org/10.3389/fonc.2022.958043
|
[24]
|
Suárez, G.M., Catalá, M., Peña, Y., Portela, S., Añé-Kourí, A.L., González, A., et al. (2022) Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Dif-ferentiated EMRA T Cells in Advanced Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Frontiers in Oncology, 12, Article ID: 823287.
https://doi.org/10.3389/fonc.2022.823287
|
[25]
|
Herrera, Z.M. and Ramos, T.C. (2014) Pilot Study of a Novel Combination of Two Therapeutic Vaccines in Advanced Non-Small-Cell Lung Cancer Patients. Cancer Immunology, Immunotherapy, 63, 737-747.
https://doi.org/10.1007/s00262-014-1552-9
|
[26]
|
Sanchez, L., Muchene, L., Lorenzo-Luaces, P., Viada, C., Rodri-guez, P.C., Alfonso, S., Crombet, T., Neninger, E., Shkedy, Z. and Lage, A. (2018) Differential Effects of Two Thera-peutic Cancer Vaccines on Short- and Long-Term Survival Populations among Patients with Advanced Lung Cancer. Seminars in Oncology, 45, 52-57.
https://doi.org/10.1053/j.seminoncol.2018.04.005
|
[27]
|
Flores Vega, Y.I., Páramo González, D.L., Alsina Sar-miento, S.C., AlsinaTul, L.E., Inguanzo Valdés, I.B., Rodríguez Machado, J., et al. (2023) Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. Journal of Cancer, 14, 874-879. https://doi.org/10.7150/jca.67189
|
[28]
|
Mancebo, A., Casacó, A., González, B., Ledón, N., Sorlozabal, J., León, A., et al. (2012) Repeated Dose Intramuscular Injection of the CIMAvax-EGF Vaccine in Sprague Dawley Rats Induces Local and Systemic Toxicity. Vaccine, 30, 3329-3338. https://doi.org/10.1016/j.vaccine.2012.01.092
|
[29]
|
Fernández Lorente, A., Acosta Brooks, S., NeningerVinageras, E., Barroso Alvarez Mdel, C., Wilkinson Brito, B., Troche Concepción, M., et al. (2013) Effect of Blockade of the EGF System on Wound Healing in Patients Vaccinated with CIMAvax® EGF. World Journal of Surgical Oncology, 11, Arti-cle No. 275.
https://doi.org/10.1186/1477-7819-11-275
|
[30]
|
Rodriguez, P.C., Neninger, E., García, B., Popa, X., Viada, C., Luaces, P., et al. (2011) Safety, Immunogenicity and Preliminary Efficacy of Multiple-Site Vaccination with an Epidermal Growth Factor (EGF) Based Cancer Vaccine in Advanced Non Small Cell Lung Cancer (NSCLC) Patients. Journal of Immune Based Therapies and Vaccines, 9, Article No. 7. https://doi.org/10.1186/1476-8518-9-7
|